Lyme Disease
ELISpot Human IFN-γ Assay

Product Details

Lyme disease, caused by the bacterium Borrelia burgdorferi, is the most common vector-borne illness in North America and Europe. Transmitted by the bite of infected ticks, Lyme disease can lead to a wide range of clinical manifestations, including erythema migrans (a characteristic skin rash), arthritis, carditis, and neurological symptoms such as meningitis and facial palsy. Early diagnosis is critical to prevent the progression to more severe, disseminated forms of the disease, which can result in long-term health complications, increased healthcare costs, and significant morbidity. Diagnosis and prompt antibiotic treatment initiated in the early stages of Lyme disease typically leads to a full recovery, whereas delayed diagnosis and treatment are associated with chronic symptoms and more complex management.

$455.00$1 820.00

Product Specifications

Product

ViraxImmune Lyme Disease ELISpot Human IFN-γ kit

Application

ELISpot

Analyte

IFN-γ

Reactivity

Human

Specificity

Human IFN-γ.

Storage

Store plates and reagents between 2 and 8°C. Peptide pool vial must be stored at -20 °C or below.

Shelf life

18 months from date of receipt.

Kit content

Peptide pools

ImmuneSelect Lyme Disease (41 peptides from Borreliella burgdorferi)

Plate

ELISpot plate precoated with IFN-γ capture antibody

Detection mAb

Biotinylated recombinant IFN-γ antibody

Enzyme conjugate

Streptavidin-ALP (Alkaline Phosphatase)

Substrate

BCIP/NBT Ready-to-use solution

Blocking agent

Bovine Serum Albumin (BSA)

Similar products